[go: up one dir, main page]

AU2001253468A1 - Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production - Google Patents

Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production

Info

Publication number
AU2001253468A1
AU2001253468A1 AU2001253468A AU5346801A AU2001253468A1 AU 2001253468 A1 AU2001253468 A1 AU 2001253468A1 AU 2001253468 A AU2001253468 A AU 2001253468A AU 5346801 A AU5346801 A AU 5346801A AU 2001253468 A1 AU2001253468 A1 AU 2001253468A1
Authority
AU
Australia
Prior art keywords
compositions
treatment
methods
lung function
fibrotic conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253468A
Inventor
Giovanni Antico
Jeffrey Farrow
Gerald Lohnas
James Melby
Lucio Miele
Aprile L. Pilon
Richard W. Welch
Laura Wiese
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Claragen Inc
Original Assignee
Claragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Claragen Inc filed Critical Claragen Inc
Publication of AU2001253468A1 publication Critical patent/AU2001253468A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001253468A 2000-04-14 2001-04-13 Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production Abandoned AU2001253468A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54992600A 2000-04-14 2000-04-14
US09/549,926 2000-04-14
PCT/US2001/012126 WO2001079285A1 (en) 2000-04-14 2001-04-13 Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production

Publications (1)

Publication Number Publication Date
AU2001253468A1 true AU2001253468A1 (en) 2001-10-30

Family

ID=24194950

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253468A Abandoned AU2001253468A1 (en) 2000-04-14 2001-04-13 Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production

Country Status (3)

Country Link
AU (1) AU2001253468A1 (en)
CA (1) CA2405946A1 (en)
WO (1) WO2001079285A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246543B2 (en) 2008-05-13 2015-08-06 Clarassance, Inc. Recombinant human CC10 and compositions thereof for use in the treatment of nasal rhinitis
US9168285B2 (en) 2009-10-15 2015-10-27 Therabron Therapeutics, Inc. Recombinant human CC10 protein for treatment of influenza and ebola
KR101597391B1 (en) 2009-10-15 2016-02-24 클라라산스, 인크. Recombinant human cc10 protein for treatment of influenza
CN118903380A (en) * 2024-07-30 2024-11-08 中山大学 Application of secretory globin 1A1 in preparation of medicament for dilating airway smooth muscle

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354269A (en) * 1991-12-20 1994-10-11 Fibrogenex, Inc. Method for treating cancer resections
US5696092A (en) * 1995-03-07 1997-12-09 George Washington University Methods and compositions for inhibiting metastasis of epithelial cell-derived cancers

Also Published As

Publication number Publication date
WO2001079285A9 (en) 2003-02-06
WO2001079285A1 (en) 2001-10-25
CA2405946A1 (en) 2001-10-25

Similar Documents

Publication Publication Date Title
AU2002257936A1 (en) Methods of well treatment
AU2001266068A1 (en) Treatment of mineral substrates
AU2002324598A1 (en) Trps as modifiers of the p53 pathway and methods of use
AU2003271944A1 (en) Methods for making water treatment compositions and compositions thereof
AU3632600A (en) Compositions and methods for the treatment of immune related diseases
AU2001286983A1 (en) Method of treatment
AU1342001A (en) Enhancement of production of camptothecins from plants
AU2001277815A1 (en) Method to determine the quality of eye-optics
AU2001253468A1 (en) Methods and compositions for the treatment of fibrotic conditions and impaired lung function and to enhance lymphocyte production
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU2001255730A1 (en) Methods and compositions for the treatment of cardiac indications
AU2001265935A1 (en) Production of biohydrolysates
AU2002246926A1 (en) 12-hydroxy-eicosatrienoic acid analogs and methods of use thereof
AU2080201A (en) Treatment of addiction disorders
AUPP132198A0 (en) Improved production of reticuline
AU2001238288A1 (en) Method and compositions for treating fibrotic diseases
AU2001262177A1 (en) Method of treatment
GB2381312B (en) Methods relating to treatment of atherosclerosis
AU4225500A (en) Methods and compositions for the treatment and prevention of lung disease
AU5812601A (en) Treatment of il-10 deficiencies
AU2001255168A1 (en) Compositions and methods for the treatment of immune related diseases
AU2001238571A1 (en) Methods of stimulating cartilage formation
AU2002340038A1 (en) Method for the selective removal of acyl-functionality attached to the 2'-hydroxy-group of paclitaxel-related derivatives
AU2002360343A1 (en) Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587, 10183, 10550, 12680, 17921, 32248, 60489 or 93804
AU3489700A (en) Oral compositions and methods of production thereof